Curaleaf Holdings (TSX:CURA) shares fell on the Toronto Stock Exchange on Friday, October 16, closing at $11.07, down 82 cents from Thursday. The U.S. cannabis operator released no company-specific news that day to explain the drop. The decline came as its hostile takeover bid for Aurora Cannabis faces mounting resistance and as a broad selloff hit U.S. growth stocks.

What happened

Curaleaf was the second-worst performer on the S&P/TSX Composite Index on Friday, behind BlackBerry and ahead of Shopify. The index itself rose 39.45 points to 36,176.55. Beneath the surface, falling stocks narrowly outnumbered gainers on the TSX, 496 to 469.

Curaleaf's latest announcements were routine. On October 14 it opened a dispensary in Wellington, Florida, and on October 15 it said it was relocating a Pennsylvania dispensary from Gettysburg to York. Neither looks like a reason for a sharp move.

The shares have been sliding for weeks. On October 15, Curaleaf traded around US$8.40 on the OTCQX, down from a September 23 peak of US$11.90.

The Aurora standoff

The biggest live issue for Curaleaf is its hostile bid for Canadian producer Aurora Cannabis. Curaleaf moved first in August with a bid worth about $272 million, valuing Aurora at $4 a share, then raised it in early October to US$5.

The revised terms pay US$1 in cash plus 0.4013 Curaleaf subordinate voting shares for each Aurora share. That means most of the offer's value depends on Curaleaf's own share price, so every drop in Curaleaf stock shrinks what Aurora holders would receive.

Aurora's board rejected the sweetened bid this week. "Curaleaf's revised offer still does not reflect the value of the company Aurora shareholders own today," said Aurora chief executive Miguel Martin.

Aurora says its special committee has approached several parties and signed confidentiality agreements as it explores alternatives, including a deal with a third party or staying independent. It has urged shareholders to reject the revised bid and not to tender early.

Curaleaf chief executive Boris Jordan called Aurora's response "grossly inadequate and negligent to its shareholders", adding that Aurora is "purposely excluding the largest cannabis company in the world." Reports have linked Organigram to possible talks with Aurora, though Organigram has not confirmed them.

Balance sheets are part of the debate. Aurora reports no debt beyond lease liabilities, while Curaleaf carries nearly US$1 billion.

The broader backdrop

Friday was rough for growth stocks. The Nasdaq composite fell 572.99 points as worries about AI spending and climbing bond yields spread through technology shares. Risk-off days like that tend to hurt indebted, growth-oriented sectors such as U.S. cannabis.

Policy has not helped either. U.S. federal rescheduling of cannabis has moved slowly since President Donald Trump signed an executive order in December 2025 to speed it up.

Curaleaf joined the S&P/TSX Composite in September 2025, which put it in front of index funds and a wider pool of Canadian investors.

What to watch next

Curaleaf's offer for Aurora remains open until December 4. A rival bid, a deal between Aurora and another party, or a further change to Curaleaf's terms could all move the stock.

Closer to home, Canada's September inflation data lands on Monday, October 19, alongside the Bank of Canada's business and consumer outlook surveys. With Governor Tiff Macklem flagging elevated energy prices and markets weighing a possible rate hike, borrowing costs remain a theme for any company carrying heavy debt.